• # LGM Pharma is a Cytarabine CAS# 147-94-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Cytarabine
  • CAS #: 147-94-4
  • Mode of Action:

    Cytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. Although the mechanism of action is not completely understood, it appears that cytarabine acts through the inhibition of DNA polymerase. A limited, but significant, incorporation of cytarabine into both DNA and RNA has also been reported.

  • Pharmacodynamics:

    Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphateplas form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle.

  • Metabolism:


  • Toxicity:

    Cytarabine syndrome may develop - it is characterized by fever, myalgia, bone pain, occasionally chest pain, maculopapular rash, conjunctivitis, and malaise.

  • IUPAC: 4-amino-1-[(2R, 3S, 4S, 5R)-3, 4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1, 2-dihydropyrimidin-2-one
  • ATC: L01BC01
  • PubChem: 6253
  • DrugBank: DB00987 (APRD00499)
  • Formula: C3H2F6O
  • Molecular Mass: 243.2166
  • Synonyms: Ara-C Arabinocytidine Arabinofuranosylcytosine Arabinosylcytosine AraC Aracytidine Aracytin Aracytine beta-Arabinosylcytosine Beta-cytosine arabinoside beta-D-Arabinosylcytosine Citarabina [INN-Spanish] Cytarabin Cytarabina cytarabine liposome injection Cytarabinoside Cytarabinum [INN-Latin] Cytosine 1-beta-D-arabinofuranoside Cytosine arabinofuranoside Cytosine arabinose Cytosine arabinoside Cytosine beta-D-arabinoside Cytosine-1-beta-D-arabinofuranoside Cytosine-beta-arabinoside Cytosine-beta-D-arabinofuranoside Cytosine, beta-D-arabinoside
  • SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
  • AHFS Code: 10:00.0
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service